| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and collaboration revenue | 1,294 | 348 | 795 | 1,497 |
| Research and development | 10,160 | 8,357 | 9,356 | 10,343 |
| General and administrative | 4,205 | 4,767 | 4,596 | 4,182 |
| Impairment of right-of-use asset | NaN | 0 | 494 | NaN |
| Total operating expenses | 14,365 | 13,124 | 14,446 | 14,525 |
| Loss from operations | -13,071 | -12,776 | -13,651 | -13,028 |
| Interest income | 910 | 710 | 423 | 453 |
| Change in fair value of derivative tranche liability | -6,188 | -28,170* | -1,800 | NaN |
| Other expense | NaN | 48* | NaN | NaN |
| Other income | 18 | NaN | -71 | -12 |
| Total other (expense) income, net | -5,260 | -27,508 | -1,448 | 441 |
| Net loss attributable to common stockholders | -18,331 | -40,284 | -15,099 | -12,587 |
| Other comprehensive income (loss) | 0 | 0 | NaN | NaN |
| Total comprehensive loss | -18,331 | -40,284 | -15,099 | -12,587 |
| Basic EPS | -0.32 | -0.747 | -0.55 | -0.62 |
| Diluted EPS | -0.32 | -0.747 | -0.55 | -0.62 |
| Basic Average Shares | 57,923,674 | 53,935,009 | 27,274,721 | 20,159,666 |
| Diluted Average Shares | 57,923,674 | 53,935,009 | 27,274,721 | 20,159,666 |
Camp4 Therapeutics Corp (CAMP)
Camp4 Therapeutics Corp (CAMP)